Overview
Abraham Heifets co-founded Atomwise, a San Francisco biotechnology company founded in 2012 that pioneered convolutional neural network approaches to structure-based drug discovery. Atomwise’s homepage describes an AI superplatform that explores the vast universe of chemical space to discover novel, drug-like molecules, with programs delivering first- and best-in-class potential in immune and inflammatory diseases.
Atomwise press history identifies Heifets as co-founder; the company has since rebranded operations as Numerion Labs per company press materials, though Atomwise remains the founding identity cited in this batch.
Role and company
Heifets co-founded Atomwise and is cited in company press materials as Co-founder and CEO during the Atomwise era. Atomwise built partnerships with pharmaceutical and biotechnology organizations applying its structure-based AI to identify small-molecule candidates for challenging targets. The homepage emphasizes a world-class team of scientists and engineers redefining how small-molecule drugs are discovered through machine learning.
Atomwise’s platform combines deep learning with medicinal chemistry workflows — a model later competitors and Flagship-backed generative biology companies extended into protein therapeutics.
Background and career context
Atomwise press materials establish Heifets as co-founder from the company’s 2012 founding in San Francisco without listing full academic credentials on the atomwise.com homepage reviewed. Heifets’ public identity is tied to early application of convolutional neural networks to molecular structure prediction — a technical contribution Atomwise marketed as differentiated from traditional high-throughput screening alone.
Company press history documents Heifets’ founding role through partnership announcements and technology milestones rather than personal biography pages — consistent with Atomwise’s science-forward corporate communications style.
Company-building or leadership context
Heifets built Atomwise from 2012 founding through partnership deals with major pharmaceutical companies and research collaborations. October 29, 2025 Numerion Labs (formerly Atomwise) published APEX research with NVIDIA on screening 10 billion compounds in under 30 seconds per company press — a throughput milestone tied to Heifets’ founding vision of ML-accelerated chemical space search.
Atomwise’s evolution toward Numerion Labs reflects a strategic shift from partnership-centric discovery services toward an integrated AI-native drug discovery organization, with leadership transitions documented on company press pages.
Public milestones
2012: Atomwise founded in San Francisco by Abraham Heifets per press history. October 29, 2025: Numerion Labs published APEX protocol research with NVIDIA (atomwise.com / numerionlabs.ai press). Atomwise homepage markets immune and inflammatory disease programs born from its AI superplatform.
Atomwise press page documents partnership and research milestones across Heifets’ tenure as co-founder, providing verifiable anchors for the company’s machine-learning drug discovery claims.
Why their work matters
Atomwise under Heifets’ co-founding leadership helped establish deep learning as a credible tool in structure-based drug discovery — a category where skepticism remained high through the early 2010s. The APEX throughput research with NVIDIA illustrates how founding-era convolutional network approaches evolved into production-scale chemical library screening protocols.
For healthcare AI readers, Atomwise represents the drug-discovery end of AI in healthcare — distinct from clinical workflow AI but sharing the 2026 imperative of demonstrating measurable outcomes beyond pilot demonstrations.
Sources and references
Primary sourcing: Atomwise homepage and press page, reviewed July 10, 2026.
- Atomwise — Homepage (atomwise.com)
- Atomwise — Press (atomwise.com)
Co-founder status and 2012 founding from Atomwise press history. Rebrand to Numerion Labs noted in company press materials.
Atomwise homepage states programs born from its superplatform deliver first- and best-in-class potential in immune and inflammatory diseases, with a world-class team of scientists and engineers redefining small-molecule drug discovery. Heifets’ co-founding role connects to this published corporate identity on atomwise.com reviewed July 2026.